CN113015751A - 一种融合蛋白及其用途 - Google Patents

一种融合蛋白及其用途 Download PDF

Info

Publication number
CN113015751A
CN113015751A CN201980075046.0A CN201980075046A CN113015751A CN 113015751 A CN113015751 A CN 113015751A CN 201980075046 A CN201980075046 A CN 201980075046A CN 113015751 A CN113015751 A CN 113015751A
Authority
CN
China
Prior art keywords
fusion protein
seq
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980075046.0A
Other languages
English (en)
Inventor
吕明
丁晓然
缪仕伟
谈彬
王学恭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen MAb Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Publication of CN113015751A publication Critical patent/CN113015751A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供的是一种融合蛋白，其包含特异性结合肿瘤相关抗原的第一结合域，以及特异性结合CD47蛋白的第二结合域；其中，所述第二结合域包含人SIRPα变体1的突变体。还提供了与所述融合蛋白相关的免疫缀合物、核酸分子、载体、组合物、细胞和制备方法，以及它们在制备药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (61)

  1. PCT国内申请，权利要求书已公开。
CN201980075046.0A 2018-11-14 2019-11-13 一种融合蛋白及其用途 Pending CN113015751A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811356690.9A CN111303293B (zh) 2018-11-14 2018-11-14 一种融合蛋白及其用途
CN2018113566909 2018-11-14
PCT/CN2019/117856 WO2020098672A1 (zh) 2018-11-14 2019-11-13 一种融合蛋白及其用途

Publications (1)

Publication Number Publication Date
CN113015751A true CN113015751A (zh) 2021-06-22

Family

ID=70731941

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811356690.9A Active CN111303293B (zh) 2018-11-14 2018-11-14 一种融合蛋白及其用途
CN201980075046.0A Pending CN113015751A (zh) 2018-11-14 2019-11-13 一种融合蛋白及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811356690.9A Active CN111303293B (zh) 2018-11-14 2018-11-14 一种融合蛋白及其用途

Country Status (11)

Country Link
US (1) US20210317230A1 (zh)
EP (1) EP3882277A4 (zh)
JP (1) JP2022513008A (zh)
KR (1) KR20210093265A (zh)
CN (2) CN111303293B (zh)
AU (1) AU2019379207A1 (zh)
BR (1) BR112021009366A2 (zh)
CA (1) CA3119400A1 (zh)
SG (1) SG11202104912SA (zh)
TW (1) TW202031687A (zh)
WO (1) WO2020098672A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
JP2023542907A (ja) * 2020-09-18 2023-10-12 イシュノス サイエンシズ ソシエテ アノニム Ｃｄ４７－ｃｄ３８二重特異性抗体
CN116178561A (zh) * 2021-11-26 2023-05-30 杭州尚健生物技术有限公司 包含SIRPα突变体的融合蛋白

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649902A (zh) * 2002-03-01 2005-08-03 免疫医疗公司 内在化抗－cd74抗体和使用方法
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
US20180030142A1 (en) * 2014-08-08 2018-02-01 The Board of Trustees of the Leland Stand Stanford Junior University Sirp alpha-antibody fusion proteins
CN108350048A (zh) * 2015-08-07 2018-07-31 阿列索治疗公司 具有SIRP-α结构域或其变体的构建体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649902A (zh) * 2002-03-01 2005-08-03 免疫医疗公司 内在化抗－cd74抗体和使用方法
CN102174108A (zh) * 2002-03-01 2011-09-07 免疫医疗公司 内在化抗-cd74抗体和使用方法
US20180030142A1 (en) * 2014-08-08 2018-02-01 The Board of Trustees of the Leland Stand Stanford Junior University Sirp alpha-antibody fusion proteins
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
CN108350048A (zh) * 2015-08-07 2018-07-31 阿列索治疗公司 具有SIRP-α结构域或其变体的构建体

Also Published As

Publication number Publication date
KR20210093265A (ko) 2021-07-27
CA3119400A1 (en) 2020-05-22
EP3882277A1 (en) 2021-09-22
BR112021009366A2 (pt) 2021-08-17
SG11202104912SA (en) 2021-06-29
TW202031687A (zh) 2020-09-01
CN111303293B (zh) 2022-08-30
CN111303293A (zh) 2020-06-19
US20210317230A1 (en) 2021-10-14
AU2019379207A1 (en) 2021-06-10
JP2022513008A (ja) 2022-02-07
EP3882277A4 (en) 2022-08-03
WO2020098672A1 (zh) 2020-05-22

Similar Documents

Publication Publication Date Title
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
US20220251154A1 (en) Fusion protein and use thereof
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
CN113015751A (zh) 一种融合蛋白及其用途
US9725519B2 (en) Antibody against transporter and use thereof
WO2020114478A1 (zh) Cd3抗体及其药物用途
WO2021098822A1 (zh) 一种双特异性抗体
CN114075289A (zh) 抗cd73的抗体及其用途
WO2021254481A1 (zh) 抗Claudin18.2抗体以及其用途
CN112661855B (zh) 含SIRPa变体的融合蛋白
WO2023093831A1 (zh) 包含SIRPα突变体的融合蛋白
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CN114478768A (zh) 抗cd73的抗体及其用途
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
WO2022068809A1 (zh) 抗cd3抗体以及其用途
TW202144412A (zh) 一種融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047979

Country of ref document: HK